OrchidPharma
A **Dhanuka** Group Company

August 14, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Symbol: **ORCHPHARMA**

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Scrip Code: **524372**

Subject: Outcome of Board Meeting – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of Schedule III and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, SEBI Master Circular no. SEBI/ HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 and in continuation to the prior intimation given by the Company on August 11, 2026 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. August 14, 2026 (commenced at 14:00 P.M. (IST) and concluded at 18:15 P.M. (IST) has *inter-alia* considered and approved unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-I of Financial Year 2026-27 ended on June 30, 2026, along with the auditors' review reports issued on the same by M/s. Singhi & Co., Statutory Auditors of the Company.

You are requested to take the above intimations on record.

Thanking You,
For **Orchid Pharma Limited**

ORCHID PHARMA LIMITED

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. as above

Orchid Pharma Limited

Regd. Office: Plot Nos. 121 – 128, 128A – 133, 138 – 151, 159 – 164, SIDCO Industrial Estate, Alathur, Chengalpattu District – 603110, Tamil Nadu, India
Ph. +91 - 44 - 2744 4471 - 78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com
CIN : L24222TN1992PLC022994

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

(All amounts are in lakhs of Indian Rupees, unless otherwise stated)

S. No.	Particulars	Standalone financial results				Consolidated financial results			
		For the quarter ended			For the year ended	For the quarter ended			For the year ended
		June 30, 2026 (Unaudited)	March 31, 2026 Revised (Audited) (Refer Note 6 & 7)	June 30, 2025 Revised (Unaudited) (Refer Note 7)	March 31, 2026 Revised (Audited) (Refer Note 7)	June 30, 2026 (Unaudited)	March 31, 2026 Revised (Audited) (Refer Note 6 & 7)	June 30, 2025 Revised (Unaudited) (Refer Note 7)	March 31, 2026 Revised (Audited) (Refer Note 7)
	Income from Operations								
1	Net Sales / Income from operations	30,417.13	36,832.71	26,318.58	1,23,277.84	30417.13	36,832.71	26,318.58	123277.84
2	Other Income	1,004.72	1,372.81	1,605.26	5,648.69	182.84	777.37	1,156.98	3641.83
3	**Total Income (1+2)**	**31,421.85**	**38,205.52**	**27,923.84**	**1,28,926.53**	**30,599.97**	**37,610.08**	**27,475.56**	**1,26,919.67**
4	**Expenses**								
	Cost of materials consumed	20,642.20	20,983.93	20,369.78	77,139.16	20642.2	20,983.93	20,369.78	77139.16
	Changes in inventories of raw material, work-in-progress, stock-in-trade and finished goods	(272.47)	3,512.34	(2,109.47)	7,138.39	(272.47)	3,512.34	(2,109.47)	7138.39
	Purchases of Stock in trade	60.65	47.59	78.79	168.72	60.65	47.59	78.79	168.72
	Employee benefit expenses	2,675.81	2,633.08	2,769.80	11,432.05	2803.79	2,761.75	2,769.80	11765.46
	Finance costs	221.23	194.97	228.48	896.15	223.02	196.39	228.48	898.43
	Depreciation and amortization expense	1,090.16	1,118.44	1,053.46	4,335.60	1094.91	1,090.31	1,053.46	4324.63
	Other expenses	5,810.55	6,426.86	5,773.54	23,621.17	5782.92	6,511.15	5,773.88	23708.71
	Total Expenses	**30,228.13**	**34,917.21**	**28,164.38**	**1,24,731.24**	**30,335.02**	**35,103.46**	**28,164.72**	**1,25,143.50**
5	**Profit / (Loss) before exceptional items and tax (3-4)**	**1,193.72**	**3,288.31**	**(240.54)**	**4,195.29**	**264.95**	**2,506.62**	**(689.16)**	**1,776.17**
6	Exceptional items (refer Note no.3)	-	(22.02)	-	(733.29)	-	(22.02)	-	(733.29)
7	**Profit / (Loss) before tax (5+6)**	**1,193.72**	**3,266.29**	**(240.54)**	**3,462.00**	**264.95**	**2,484.60**	**(689.16)**	**1,042.88**
8	**Tax expense**								
	Current tax	-	-	-	-			-	
	Tax adjustments of earliear years					-	-	-	-
	Deferred tax	-	-	-	-	7.23	0.17	-	(19.16)
	Total Tax Expenses	-	-	-	-	7.23	0.17	-	(19.16)
9	**Profit / (Loss) for the period before share of profit of Associates (7-8)**	**1,193.72**	**3,266.29**	**(240.54)**	**3,462.00**	**257.72**	**2,484.43**	**(689.16)**	**1,062.04**

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd...)

S. No.	Particulars	Standalone financial results				Consolidated financial results			
		For the quarter ended			For the year ended	For the quarter ended			For the year ended
		June 30, 2026 (Unaudited)	March 31, 2026 Revised (Audited) (Refer Note 6 & 7)	June 30, 2025 Revised (Unaudited) (Refer Note 7)	March 31, 2026 Revised (Audited) (Refer Note 7)	June 30, 2026 (Unaudited)	March 31, 2026 Revised (Audited) (Refer Note 6 & 7)	June 30, 2025 Revised (Unaudited) (Refer Note 7)	March 31, 2026 Revised (Audited) (Refer Note 7)
10	**Profit / (Loss) for the period before share of profit of Associates**	**1,193.72**	**3,266.29**	**(240.54)**	**3,462.00**	**257.72**	**2,484.43**	**(689.16)**	**1,062.04**
11	**Add: Share of Profit/ (Loss) of Associates**	-	-	-	-	64.72	99.51	119.94	(66.13)
12	**Profit / (Loss) for the period (10+11)**	**1,193.72**	**3,266.29**	**(240.54)**	**3,462.00**	**322.44**	**2,583.94**	**(569.22)**	**995.91**
13	**Other comprehensive income, net of income tax**								
	a) (i) items that will not be reclassified to profit or loss	0.64	130.27	(15.48)	131.76	0.64	130.27	(15.48)	131.76
	(ii) income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	b) (i) items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Total other comprehensive income/ (loss), net of income tax	**0.64**	**130.27**	**(15.48)**	**131.76**	**0.64**	**130.27**	**(15.48)**	**131.76**
14	**Total comprehensive income/ (Loss) for the period (12+13)**	**1,194.36**	**3,396.56**	**(256.02)**	**3,593.76**	**323.08**	**2,714.21**	**(584.70)**	**1,127.67**
15	Paid-up equity share capital	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52	5,988.52
	(Including Shares pending allotment on account of Merger)								
	Other Equity				1,58,679.07				1,50,442.18
	Face value per share (Rs)	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
16	**Earnings per equity share *:**								
	- Basic (Rs.)	1.99	5.45	(0.40)	5.78	0.54	4.31	(0.95)	1.66
	- Diluted (Rs.)	1.99	5.45	(0.40)	5.78	0.54	4.31	(0.95)	1.66

'* EPS for the quarters are not annualised

SINGHI & CO. Chartered Accountants

ORCHID PHARMA LIMITED

Orchid Pharma Limited

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd...)

Notes:

1 The above results for the quarter ended June 30, 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 14, 2026.The statutory auditors of the company have expressed an unmodified conclusion on the unaudited Standalone and Consolidated results

2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable.

3 a)The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet to be notified even as on date.

During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711.27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under "Exceptional items".

Thereafter, based on subsequent FAQ's and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to Rs.733.29 Lakhs. Hence the differential provision of Rs.22.02 Lakhs has been made in the March 2026 quarter under "Exceptional items".

The Company continues to monitor the finalisation of Central / State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments.

4 The entire net Proceeds of Rs.39180 Lakhs riased on 27th June 2023 by way of Qualified Institutional Placement (QIP) was received by the Company and the Statement of Net funds raised and its utilisation as on June 30, 2026 is furnished below :

Statement of QIP Net Funds raised and utilisation

Particulars	Amount as stated in the Offer Document (Rs. in Lakhs) (Revised)	Total amount utilised upto June 30, 2026 (Rs. In Lakhs)	* Balance amount as on June 30, 2026 kept in Fixed deposits (Rs. In Lakhs)	Remarks
1) Investment in OBPL (subsidiary) for setting up Jammu Manufacturing Facility	13,500	9,762	3,738	
2) Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the Company	19,546	19,546	-	
3) Funding capital expenditure requirements for setting up a new block at the API Facility of the Company in Alathur, Tamil Nadu	36	36	-	
4) General corporate purposes	6,372	6,372	-	#
Total	**39,454**	**35,716**	**3,738**	

#As per the QIP offer document the amount allocated for General Corporate Purpose (GCP) was ₹ 6098 Lakhs which was based on the proposed net proceeds after issue expenses being ₹ 39180 Lakhs. However, net proceeds transferred to Monitoring Account was ₹ 39,454 Lakhs as against the proposed Net Proceeds of ₹ 39,180 Lakhs, therefore the surplus amount of₹ 274 Lakhs has been included in the GCP Balance as on June 30, 2026 . The Allocation among the objects has been revised vide Shareholder's resolution dated September 20, 2025

* Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits.

SINGHI & CO. ★ Chartered Accountants ★

ORCHID PHARMA LIMITED ★

Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd...)

5 The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable.

6 The figures for the quarter ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the financial year which were subjected to limited review.

7 Pursuant to the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited ("Transferor Company") and Orchid Pharma Limited ("Company" or "Transferee Company") and their respective shareholders and creditors ("Scheme"), sanctioned by the Hon'ble National Company Law Tribunal, Chennai Bench ("NCLT") vide its order dated June 05, 2026, the Transferor Company has been amalgamated with and into the Company. The Scheme has an appointed date of April 01, 2024 and became effective on July 10, 2026 upon filing of the certified copy of the NCLT order with the Registrar of Companies, Chennai. In accordance with the terms of the Scheme and the applicable provisions of Ind AS, the amalgamation has been accounted for from the appointed date. Accordingly, the financial results for the quarter ended June 30, 2026 and the comparative periods presented therein have been prepared/restated, respectively, to give effect to the amalgamation from the appointed date, as applicable.

8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29, 2025 and August 01, 2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India.

9 The Company had acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, 2025.

10 Figures of the previous period have been regroupted/reclassified /restated wherever considered necessary

For and on behalf of the Board

SINGHI & CO. Chartered Accountants

Place: Gurugram
Date : August 14, 2026

Manish Dhanuka
Managing Director
Din: 00238798

ORCHID PHARMA LIMITED

Initiated for identification purposes

Singhi & Co.
Chartered Accountants
Unit 11-D, 11th Floor, Ega Trade Centre, 809, Poonamallee High Road, Kilpauk, Chennai-600 010 India
Ph: +91 44 42918459, E-mail :chennai@singhico.com Website : www.singhico.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Orchid Pharma Limited** ("the Company") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards ('IND AS') prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

Other Matter:

5. The figures for the quarter ended March 31, 2026 as reported in the Statement is the balancing figures between audited figures in respect of the full financial year ended on March 31, 2026 and the published year to date figures upto the end of the third quarter ended December 31, 2025. Also, the figures up to the end of the third quarter had only been reviewed by us as required under the Listing Regulations and not subjected to audit. Our Conclusion is not modified in respect of this matter.

For Singhi & Co.
Chartered Accountants
Firm Regn. No. 302049E

Sudesh Choraria
Partner
Membership No.204936
UDIN: 26204936ILAYYC8225

Place: Mumbai
Date: August 14, 2026

Singhi & Co.
Chartered Accountants
Unit 11-D, 11th Floor, Ega Trade Centre, 809, Poonamallee High Road, Kilpauk, Chennai-600 010 India
Ph: +91 44 42918459, E-mail :chennai@singhico.com Website : www.singhico.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Orchid Pharma Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Orchid Pharma Limited** (hereinafter referred to as "the Parent Company") and its subsidiaries (the Parent Company and its Subsidiaries together referred to as " the Group") and its associate for the quarter ended June 30,2026 ("the Statement") attached herewith being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent Company's Management and has been approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to issue a conclusion on these financial results based on the review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
   i) Orchid Pharmaceuticals Inc., USA
   ii) Bexel Pharmaceuticals Inc., USA
   iii) Diakron Pharmaceuticals, Inc. USA
   iv) Orchid Bio-Pharma Limited
   v) Orchid Pharma Europe GmbH (w.e.f. 30th July 2025)

   The unaudited consolidated financial results also include the results of M/s Orbion Pharmaceuticals Private Limited, an associate company accounted under equity method.

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

5. **Other matters**:

a) We did not review the financial information of 1 subsidiary included in the statement, whose financial information reflects, revenue from operations of Rs. Nil, net profit after tax of Rs. (19.41) lakhs, total comprehensive income after tax of Rs. (19.41) lakhs for the quarter ended June 30, 2026 respectively as considered in this statement. These financial information have been reviewed by other auditors whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.

b) We did not review the interim financial results of 4 subsidiaries whose financial information reflects revenue from operations of Rs. Nil and Rs. Nil, net profit after tax of Rs. (161.19) lakhs, total comprehensive income after tax of Rs. (161.19) lakhs for the quarter ended June 30, 2026 respectively as considered in the unaudited consolidated financial results.

We also did not review the Group's share of net Profit / (loss) (after tax) of Rs.64.72 Lakhs of the associate for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial statements.

The financial information of the above subsidiaries and the associate are unaudited and have been furnished to us by the management and our conclusion on the unaudited consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and associate, is based solely on such unaudited financial results furnished to us.

Our Conclusion is not modified in respect of the above matters.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.,
Chartered Accountants
Firm Regn. No. 302049E

SINGHI & CO. Chartered Accountants

Sudesh Choraria
Partner
Membership No.204936
UDIN: 26204936AHVAKZ3329

Place: Mumbai
Date: August 14, 2026